| 生物活性 |
Macranthoside B is an apoptosis inducer with in vitro and in vivo anticancer activity that induces autophagy and ferroptosis in cancer cells and, by inducing intracellular ROS accumulation, activating AMPK, inhibiting the phosphorylation of mTOR and P70S6 kinase, and regulating Bcl-2/Bax expression, activates caspase-3, caspase-9, and the intrinsic caspase cascade, induces PARP cleavage/degradation, inhibits the NRF2 signaling pathway, and disrupts iron homeostasis through NCOA4-dependent ferritinophagy, upregulates Lip-ROS, reduces mitochondrial membrane potential, and activates the JNK pathway, thereby being useful for research on ovarian cancer, liver cancer, gastric cancer, breast cancer, colon cancer, glioma, melanoma, esophagogastric junction adenocarcinoma, and cervical cancer. |
体外研究 (In Vitro) |
Macranthoside B (1.25-20 μM; 24-72 h) 可呈时间和浓度依赖性抑制人卵巢癌 A2780 细胞增殖,其 IC50 值介于 7.52 μM 至 14.66 μM 之间,且对人正常胚胎肺成纤维细胞 HFL1 的细胞毒性较低。 Macranthoside B (5-20 μM; 6 h treatment, followed by 15 days of growth) 可呈剂量依赖性抑制人卵巢癌 A2780 细胞的克隆形成能力,其 IC50 为 8.46 μM。 Macranthoside B (5-20 μM; 48 h) 可呈剂量依赖性地激活人卵巢癌 A2780 细胞中的 AMPK 并抑制 mTOR/P70S6K 通路。 Macranthoside B (2.55-80 μM; 48 h) 可在体外强效抑制人源 HepG2、MGC-803、MCF-7、SW1116、U251,大鼠源 C6 以及小鼠源 B16F1、B16F10 癌细胞的增殖,其 IC50 值介于 10 μM 至 18 μM 之间。 Macranthoside B (0-40 μM; 24, 48 h) 以浓度依赖方式抑制 SKGT-4、OE-19 和 OE-33 这三种 AEG 细胞的活力,其作用 48 h 的 IC50 值介于 4.74 至 8.59 μM 之间,且对正常 NGEC 细胞的活性较弱。 Macranthoside B (8-10 μM; 24 h) 可呈浓度依赖性抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞的集落形成能力,在 8 μM 和 10 μM 浓度下可产生显著抑制作用。 Macranthoside B (10-15 μM; 48 h) 以浓度依赖的方式抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞的增殖,在 10 μM 和 15 μM 浓度下 EDU 阳性细胞数量显著减少。 Macranthoside B (8-10 μM; 36 h) 可呈浓度依赖性抑制 SKGT-4 和 OE-19 型食管胃结合部腺癌 (AEG) 细胞的迁移与侵袭,在 8 μM 和 10 μM 浓度下抑制作用显著。 Macranthoside B (5-20 μM; 24-48 h) 可呈剂量依赖性诱导人卵巢癌 A2780 细胞凋亡,而自噬抑制剂 3-Methyladenine (MS-H80278) 或泛半胱天冬酶抑制剂 Z-VAD-FMK (MS-L66221) 的预处理可减弱该凋亡效应。 Macranthoside B (5-20 μM; 48 h) 可呈剂量依赖性上调人卵巢癌 A2780 细胞中的促凋亡标志物 (活化的 caspase-3、活化的 caspase-9、活化的 PARP) 和自噬标志物 LC3-II;抑制自噬会降低细胞凋亡水平,而抑制凋亡则会增强自噬,抑制 ROS 或 AMPK 则可同时降低细胞凋亡与自噬水平。 Macranthoside B (20 μM; 48 h) 可在孵育 48 h 后诱导人卵巢癌 A2780 细胞发生凋亡性细胞核形态改变。 Macranthoside B (10-20 μM) 可剂量依赖性地诱导表达 GFP-LC3 的人卵巢癌 A2780 细胞形成自噬点状结构。 Macranthoside B (15 μM; 48 h) 可激活 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的自噬作用,增加 LC3B 斑点、自噬泡以及 LC3B II/P62 蛋白水平,同时抑制自噬流。 Macranthoside B (10 μM; 24-48 h) 可升高人卵巢癌 A2780 细胞内的 ROS 水平。 Macranthoside B (30-40 μM; 4 h) 可在人肝癌 HepG2 细胞中诱导具有早期凋亡特征的形态学改变,包括细胞变圆、染色质凝集和核固缩。 Macranthoside B (40 μM; 4 h) 可诱导人肝癌 HepG2 细胞发生凋亡,其中 39.02%的细胞进入早期凋亡阶段,13.45%的细胞进入晚期凋亡/坏死阶段。 Macranthoside B (30-40 μM; 4 h) 可通过线粒体介导的通路诱导人肝癌 HepG2 细胞发生凋亡,激活 caspase-9 和 caspase-3,切割 PARP,上调 Bax 蛋白表达,下调 Bcl-2 蛋白表达,并提高 Bax/Bcl-2 比值。 Macranthoside B (15 μM; 48 h) 处理 SKGT-4 食管腺癌 (AEG) 细胞可改变 1800 余种基因的表达,上调与氧化还原酶活性、铁死亡及自噬相关的通路。 Macranthoside B (10-15 μM; 48 h) 可诱导 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中脂质活性氧呈浓度依赖性累积,在 10 μM 和 15 μM 浓度下出现显著升高。 Macranthoside B (0-15 μM; 0-48 h) 以浓度和时间依赖的方式下调 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的 GPX4 蛋白水平,分别将其水平降至对照组的 0.1 和 0.5。 Macranthoside B (0-15 μM; 0-48 h) 以浓度和时间依赖的方式上调 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中 NCOA4 和 FTH1 的蛋白水平,激活 NCOA4 介导的铁蛋白自噬。 Macranthoside B (0-15 μM; 48 h) 可抑制 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的 NRF2,下调 NRF2 蛋白水平及其下游靶基因 HERC2 和 VAMP8,从而破坏铁稳态。 Macranthoside B (48 h) 会破坏 SKGT-4 和 OE-19 食管腺癌 (AEG) 细胞中的铁稳态,显著提升细胞内 Fe2+水平。 Macranthoside B 可通过 ROS 过度生成及 MAPKs/JNK 通路激活,增强 Paclitaxel (HY-B0015) 诱导的人宫颈腺癌 HeLa 细胞凋亡。
Cell Viability Assay
| Cell Line: |
Human ovarian carcinoma A2780 cells, human embryonic lung fibroblast HFL1 cells |
| Concentration: |
1.25 μM, 2.5 μM, 5 μM, 1 μM, 20 μM |
| Incubation Time: |
24 h, 48 h, 72 h |
| Result: |
Inhibited A2780 cell viability in a concentration- and time-dependent manner, with IC50 values of 14.66 μM (24 h), 11.23 μM (48 h), 7.52 μM (72 h). Exhibited IC50 values of 59.58 μM (24 h), 42.34 μM (48 h), 38.44 μM (72 h) in HFL1 cells, showing greater cytotoxicity toward tumor cells than normal cells. |
Western Blot Analysis
| Cell Line: |
human ovarian carcinoma A2780 cells |
| Concentration: |
5 μM, 10 μM, 20 μM (48 h incubation); 10 μM (48 h incubation with inhibitor pretreatment or beclin 1 siRNA transfection) |
| Incubation Time: |
48 h |
| Result: |
Increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP, and LC3-II in a concentration-dependent manner at 5, 10, 20 μM for 48 h (cleaved caspase-3 levels relative to β-actin: 4.4, 20.0, 24.7; cleaved caspase-9: 10.5, 14.9, 23.5; cleaved PARP: 2.2, 3.4, 4.7; LC3-II: 3.4, 12.4, 24.9). Decreased levels of cleaved caspase-3 (from 10.0 to 8.5), cleaved caspase-9 (from 2.0 to 1.8), cleaved PARP (from 1.0 to 0.5), and LC3-II (from 1.0 to 0.23) when cells were pretreated with 5 mM 3-methyladenine prior to 10 μM treatment. Decreased LC3-II levels (from 1.0 to 0.19) and cleaved PARP levels (from 1.0 to 0.05) when cells were transfected with beclin 1 siRNA prior to 10 μM treatment. Decreased levels of cleaved caspase-3 (from 2.1 to 0.2), cleaved caspase-9 (from 6.5 to 2.7), cleaved PARP (from 4.8 to 1.9), but increased LC3-II levels (from 2.0 to 3.8) when cells were pretreated with 10 μM Z-VAD-FMK prior to 10 μM treatment. Decreased levels of cleaved caspase-3 (from 2.2 to 0.8), cleaved caspase-9 (from 1.7 to 1.5), cleaved PARP (from 1.6 to 0.7), and LC3-II (from 5.0 to 2.5) when cells were pretreated with 5 mM NAC prior to 10 μM treatment. Decreased levels of cleaved caspase-3 (from 1.8 to 0.7) and LC3-II (from 1.6 to 0.7) when cells were pretreated with 10 μM Compound C prior to 10 μM treatment. |
Western Blot Analysis
| Cell Line: |
human ovarian carcinoma A2780 cells |
| Concentration: |
5 μM, 10 μM, 20 μM (48 h incubation); 10 μM (48 h incubation with inhibitor pretreatment) |
| Incubation Time: |
48 h |
| Result: |
Increased p-AMPK levels relative to β-actin (13.0, 18.9, 23.9) and decreased p-mTOR (0.9, 0.8, 0.6) and p-P70S6K (0.6, 0.4, 0.1) levels in a concentration-dependent manner at 5, 10, 20 μM for 48 h. Decreased p-AMPK (from 2.4 to 1.1), p-mTOR (from 0.4 to 0.9), and p-P70S6K (from 0.5 to 1.0) levels when cells were pretreated with 5 mM NAC prior to 10 μM treatment. Decreased p-AMPK (from 5.1 to 0.3), p-mTOR (from 0.3 to 0.9), and p-P70S6K (from 0.4 to 0.6) levels when cells were pretreated with 10 μM Compound C prior to 10 μM treatment. |
Cell Viability Assay
| Cell Line: |
human hepatoma HepG2, human gastric cancer MGC-803, human mammary adenocarcinoma MCF-7, human colonic carcinoma SW1116, human glioblastoma U251, rat glioma C6, mouse melanoma B16F1, mouse melanoma B16F10 |
| Concentration: |
2.55-80 μM; 4.25-48 μM (HepG2 cells) |
| Incubation Time: |
48 h |
| Result: |
Inhibited HepG2 cell viability with inhibitory rates of 2.58%, 23.21%, 55.89%, 86.55%, and 98.14% at concentrations of 4.25, 7.08, 14.75, 23.04, and 48 μM respectively, with an IC50 of 10 μM. Inhibited viability of all tested cell lines with IC50 values: MGC-803 (16 μM), MCF-7 (12 μM), SW1116 (14 μM), U251 (18 μM), C6 (14 μM), B16F1 (15 μM), and B16F10 (16 μM). |
Apoptosis Analysis
| Cell Line: |
Human hepatoma HepG2 |
| Concentration: |
40 μM |
| Incubation Time: |
4 h |
| Result: |
Increased the percentage of early apoptotic cells to 39.02% and the percentage of late apoptotic/necrotic cells to 13.45%, compared to control cells. |
Western Blot Analysis
| Cell Line: |
human hepatoma HepG2 |
| Concentration: |
30 μM, 40 μM |
| Incubation Time: |
4 h |
| Result: |
Increased cleaved PARP levels in a concentration-dependent manner. Decreased procaspase-9 expression significantly, decreased procaspase-3 expression slightly, and increased levels of activated caspase-3 p17 and p12 subunits. Increased Bax protein levels by 82% and 113% at 30 μM and 40 μM respectively, decreased Bcl-2 protein levels slightly, resulting in a notable increase in the Bax/Bcl-2 ratio. |
Cell Viability Assay
| Cell Line: |
normal gastric epithelial cell line (NGEC), adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19, OE-33 |
| Concentration: |
0, 5, 10, 20, 30, 40 μM |
| Incubation Time: |
24 h; 48 h |
| Result: |
Inhibited AEG cell viability in a concentration-dependent manner, with normal NGEC cells showing lower sensitivity. Exhibited 24 h IC50 values of 9.51 μM (SKGT-4), 12.70 μM (OE-19), 10.98 μM (OE-33), and 22.80 μM (NGEC). Exhibited 48 h IC50 values of 8.59 μM (SKGT-4), 8.47 μM (OE-19), 4.74 μM (OE-33), and 11.69 μM (NGEC). |
Cell Proliferation Assay
| Cell Line: |
adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19 |
| Concentration: |
0, 8, 10 μM |
| Incubation Time: |
24 h, followed by 15-20 days of drug-free growth |
| Result: |
Reduced the number of colonies in SKGT-4 and OE-19 cells in a concentration-dependent manner. Caused statistically significant decreases (***p < 0.001) at both 8 μM and 10 μM compared to the control. |
Cell Proliferation Assay
| Cell Line: |
adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19 |
| Concentration: |
0, 10, 15 μM |
| Incubation Time: |
48 h |
| Result: |
Reduced the EDU-positive cell rate in SKGT-4 and OE-19 cells in a concentration-dependent manner. Caused statistically significant decreases (**p < 0.01, ***p < 0.001) at 10 μM and 15 μM compared to the control. |
Western Blot Analysis
| Cell Line: |
adenocarcinoma of the esophagogastric junction (AEG) cell lines SKGT-4, OE-19 |
| Concentration: |
0, 5, 10, 15 μM |
...(内容过长已截断)
体内研究 (In Vivo) |
Macranthoside B (5 mg/kg;静脉注射;每 2 天 1 次;共 14 天) 在 HepG2 异种小鼠移植瘤模型中展现体内抗肿瘤活性,肿瘤生长抑制率达 53.29%。
| Animal Model: |
Athymic BALB/cA nude mice (female, 35-40 days old, 18-22 g, subcutaneous implantation of HepG2 cells) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; every two days; 14 days |
| Result: |
Achieved 53.29% inhibition of tumor growth compared to vehicle control. Significantly reduced relative tumor volume. Lowered excised tumor weights compared to vehicle control. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
1075.24 |
| 分子式 |
C53H86O22 |
| CAS No. |
146100-02-9 |
| 别名 |
灰毡毛忍冬次皂苷乙 |
| 体内实验配方 |
10% DMSO+90% Saline: 6 mg/mL (5.58 mM), Solution. ![]() 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
4°C, sealed storage, away from moisture and light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 100 mg/mL (93.00 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 0.9300 mL | 4.6501 mL | 9.3002 mL | 23.2506 mL | | 5 mM | 0.1860 mL | 0.9300 mL | 1.8600 mL | 4.6501 mL | | 10 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL | 2.3251 mL | | 15 mM | 0.0620 mL | 0.3100 mL | 0.6200 mL | 1.5500 mL | | 20 mM | 0.0465 mL | 0.2325 mL | 0.4650 mL | 1.1625 mL | | 25 mM | 0.0372 mL | 0.1860 mL | 0.3720 mL | 0.9300 mL | | 30 mM | 0.0310 mL | 0.1550 mL | 0.3100 mL | 0.7750 mL | | 40 mM | 0.0233 mL | 0.1163 mL | 0.2325 mL | 0.5813 mL | | 50 mM | 0.0186 mL | 0.0930 mL | 0.1860 mL | 0.4650 mL | | 60 mM | 0.0155 mL | 0.0775 mL | 0.1550 mL | 0.3875 mL | | 80 mM | 0.0116 mL | 0.0581 mL | 0.1163 mL | 0.2906 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|